FDA Approves First-Ever Blood Test for Diagnosing Alzheimer’s Disease
Pan-African Journal of Health and Psychological Sciences · 04.04.2026 · 2 (2)
DOI: 10.64261/9hs6aj83 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pan-African Journal of Health and Psychological Sciences, online erschienen am 04.04.2026. Verfasst von Aadarsh Kumar und 4 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by amyloid plaques and neurofibrillary tangles, leading to cognitive decline and dementia. With a rapidly aging global population, its prevalence is rising significantly, posing major public health challenges in countries like United States and India. Early diagnosis remains difficult due to limited awareness, high costs, and reliance on invasive or resource-intensive methods such as PET imaging and cerebrospinal fluid analysis. The recent approval by the U.S. Food and Drug Administration of the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio marks a transformative advancement in Alzheimer’s diagnostics. This first-of-its-kind blood test measures key biomarkers, offering a less invasive, accessible, and cost-effective alternative for detecting disease-related changes in individuals with cognitive impairment. Clinical studies demonstrate high concordance with established diagnostic methods, supporting its role as a reliable screening tool when combined with comprehensive clinical evaluation. This innovation has significant implications for early detection, patient care planning, and healthcare system efficiency by enabling timely interventions and reducing diagnostic burden. However, limitations such as imperfect accuracy, ethical concerns, and the need for confirmatory testing remain. Overall, blood-based diagnostics represent a promising step toward more accessible, personalized, and proactive management of Alzheimer’s disease, though further validation and equitable global implementation are essential.
Zitieren
APA
Kumar, A., Kumar, A., Islam, M. M., Judder, M. I., & Ashraf, R. (2026). FDA Approves First-Ever Blood Test for Diagnosing Alzheimer’s Disease. Pan-African Journal of Health and Psychological Sciences, 2(2). https://doi.org/10.64261/9hs6aj83
Vancouver
Kumar A, Kumar A, Islam MM, Judder MI, Ashraf R. FDA Approves First-Ever Blood Test for Diagnosing Alzheimer’s Disease. Pan-African Journal of Health and Psychological Sciences. 2026;2(2). doi:10.64261/9hs6aj83
BibTeX
@article{Kumar2026,
author = {Kumar, Aadarsh and Kumar, Abhishek and Islam, Md Moidul and Judder, Moidul Islam and Ashraf, Ruhit},
title = {FDA Approves First-Ever Blood Test for Diagnosing Alzheimer’s Disease},
journal = {Pan-African Journal of Health and Psychological Sciences},
year = {2026},
volume = {2},
number = {2},
doi = {10.64261/9hs6aj83}
}
EUVIMED